Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Rhea-AI Summary
Amarin (NASDAQ: AMRN) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A pre-market press release will be issued, followed by a conference call with senior management at 8:00 a.m. ET.
Investors can join via telephone (US: 888-506-0062; international: 973-528-0011, access code 675507) or via webcast on the company Investor Relations website. A replay will be available online and by phone through August 25, 2026.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AMRN is up 1.83% with mixed peer moves: SCLX +1.36%, KMDA +0.97%, ESPR +2.73%, EBS flat, OGN -1.26%. No broad, aligned sector momentum is indicated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Franchise positioning | Positive | -3.5% | Highlighted triglyceride therapies and VASCEPA/VAZKEPA positioning with REDUCE-IT data. |
| Jan 08 | Prelim financials | Positive | +16.9% | Preliminary 2025 results with positive Q4 cash flow and strong cash balance. |
| Nov 09 | Clinical data update | Positive | +0.9% | REDUCE-IT aspirin analysis showing significant cardiovascular event reductions. |
| Nov 03 | Conference preview | Neutral | -3.9% | Planned REDUCE-IT analyses and EPA mechanism data at AHA 2025 sessions. |
| Oct 29 | Quarterly earnings | Positive | -11.3% | Q3 2025 revenue growth and margin improvement amid ongoing operating losses. |
Recent positive fundamental or clinical updates have sometimes seen weak or negative next-day reactions, especially around conferences and detailed earnings releases.
Over the past few months, Amarin has emphasized its VASCEPA/VAZKEPA franchise, new analyses from the REDUCE-IT study, and a shift toward a partnered global commercial model. Key updates included preliminary 2025 financial highlights with positive cash flow, a Recordati licensing deal, and Q3 2025 results showing year-over-year revenue growth but continued losses. Conference-related announcements and scientific data have produced mixed price reactions. Today’s scheduling of the Q4 and full-year 2025 earnings call fits into this ongoing cadence of financial and scientific disclosures.
Market Pulse Summary
This announcement sets the timeline for Amarin’s fourth quarter and full-year 2025 financial results, with a conference call on February 25, 2026. In recent quarters, the company has highlighted revenue growth, restructuring efforts, and expanding global partnerships, with share-price reactions varying around these events. Investors monitoring this update may focus on cash trends, profitability progress, and commercialization metrics compared with the preliminary 2025 figures and prior quarterly results.
AI-generated analysis. Not financial advice.
DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.
Information on how to participate is as follows.
Access to the live call:
Via telephone: Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 675507
Via online: A webcast of the call will be available on the Investor Relations section of the Company's website at www.amarincorp.com.
Access to the replay:
Via telephone: Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Access Code: 53567
Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website at www.amarincorp.com, beginning shortly after the end of the live call and available until 8/25/26.
About Amarin
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally through a syndicate of reputable and well-established partners with significant geographic expertise, covering over 90 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Media Inquiries:
Tegan Berry
Amarin Corporation plc
PR@amarincorp.com
Investor Inquiries:
Devin Sullivan & Conor Rodriguez
The Equity Group on Behalf of Amarin
dsullivan@theequitygroup.com or crodriguez@theequitygroup.com
Investor.relations@amarincorp.com
FAQ
When will Amarin (AMRN) report Q4 and full year 2025 results?
How can investors join the Amarin (AMRN) February 25, 2026 conference call?
Where will the Amarin (AMRN) webcast and replay be available after the February 25, 2026 call?
What time is Amarin's (AMRN) management conference call on February 25, 2026?
Will there be a phone replay after Amarin's (AMRN) February 25, 2026 call and how to access it?
